Brief: Inhibikase Therapeutics Regains Compliance With Nasdaq Listing Requirements
17/07/2023 21:29
July 17 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ
LISTING
REQUIREMENTS
Source text for Eikon: ID:nPn2R2Tw2a
Further company coverage: IKT.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share